Research Library

Overview

A synthetic peptide that acts as an agonist at the GLP-1, GIP, and glucagon receptors simultaneously. Studied in published research for its effects on metabolic regulation and body composition in preclinical and clinical models.

Mechanism of Action

Retatrutide engages three distinct receptor pathways concurrently. GLP-1 receptor agonism slows gastric emptying and reduces caloric intake via central satiety signaling. GIP receptor co-activation potentiates the insulin response and has been associated with enhanced adipose-tissue lipolysis. Glucagon receptor activity raises basal metabolic rate and hepatic glucose output, contributing an energy-expenditure component absent from mono- and dual-agonist models.

Published Research Highlights

• Greater body-weight reduction vs. dual agonists reported in published preclinical and Phase 2 models
• Improvements in insulin sensitivity, fasting glucose, and lipid profiles observed across metabolic studies
• Studied in the context of non-alcoholic fatty liver disease (NAFLD) and hepatic steatosis
• GHRH-analog (Tesamorelin) co-administration examined in related visceral-fat research

Research Summary

A mechanistic review of retatrutide's simultaneous agonism at GLP-1, GIP, and glucagon receptors. Covers the pharmacological rationale for triple agonism over dual or single agonist approaches, and differential effects on energy expenditure and body composition across published research. Also addresses observed interactions with the GH axis, which have prompted concurrent study of GHRH analogs in related metabolic research contexts.

Overview

A 15-amino-acid peptide derived from a protein found in gastric juice. Extensively studied in preclinical models for tissue repair, gastroprotection, and tendon healing.

Mechanism of Action

BPC-157 promotes angiogenesis and upregulates growth-factor expression at injury sites through interaction with the nitric oxide (NO) system. It modulates VEGF and EGF signaling pathways, accelerating vascular ingrowth into damaged tissue. Rodent research also reports interaction with dopaminergic, serotonergic, and GABAergic systems, suggesting CNS-relevant activity beyond peripheral repair.

Published Research Highlights

• Accelerated tendon-to-bone healing documented in multiple rodent injury models
• Gastroprotection against NSAID- and ethanol-induced ulceration in preclinical studies
• Systemic protective effect observed via both local injection and distal administration
• Studied for neurological protection and motoneuron recovery in CNS research

Research Summary

A comprehensive review of body protection compound-157's gastroprotective activity, role in tendon repair, and modulation of growth hormone receptor expression. Covers both acute injury models and longer-term regenerative outcomes across multiple tissue types.

Overview

A naturally occurring copper-binding tripeptide first isolated from human plasma, with documented roles in wound healing, collagen synthesis, and antioxidant activity across skin and tissue models.

Mechanism of Action

GHK-Cu chelates copper(II) ions and delivers them to cell-surface receptors involved in metalloenzyme activation, driving upregulation of collagen I, III, and elastin synthesis in dermal fibroblasts. The complex also modulates inflammatory cytokines (TNF-α, IL-6) and stimulates superoxide dismutase (SOD) expression, reducing oxidative damage in wound environments.

Published Research Highlights

• Upregulation of collagen I and III synthesis in fibroblast culture models
• Reduced pro-inflammatory cytokine expression (TNF-α, IL-6) in tissue-repair studies
• Nerve growth factor (NGF) activity reported in neurological research models
• Studied in skin, hair-follicle, bone, and intestinal tissue-repair contexts

Research Summary

Review of glycine-histidine-lysine copper peptide's role in wound repair, collagen and elastin stimulation, antioxidant gene expression, and nerve regeneration in preclinical models. Covers both topical and systemic research applications, with particular attention to skin tissue remodeling pathways.

Overview

A stabilized 44-amino-acid analog of growth hormone-releasing hormone that stimulates pulsatile GH secretion from the pituitary. Studied alongside GLP-1 receptor agonists in metabolic research.

Mechanism of Action

Tesamorelin is stabilized by a trans-3-hexenoic acid modification that extends its half-life. It binds pituitary GHRH receptors to stimulate endogenous, pulsatile growth hormone release, preserving the physiological GH feedback loop rather than bypassing it as exogenous GH does. This maintains downstream IGF-1 axis signaling and avoids the tachyphylaxis observed with continuous GH administration.

Published Research Highlights

• Preserves physiological GH pulsatility vs. continuous exogenous GH administration
• Studied for visceral adipose-tissue reduction in metabolic and lipodystrophy models
• Maintains IGF-1 signaling without suppressing hypothalamic feedback mechanisms
• Co-administration with GLP-1/GIP agonists (e.g., Retatrutide) examined in published research

Research Summary

Examination of tesamorelin's mechanism as a stabilized growth hormone-releasing hormone analog, its effects on pulsatile GH secretion and IGF-1 levels, and its application across metabolic research. Includes a review of published literature examining GH axis dynamics in studies where GLP-1 receptor agonism is present as a co-variable.